Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance. To address this problem, we set out to identify druggable mechanisms that convey resistance to proteasome inhibitors (PIs; e.g., bortezomib), which are cornerstone agents in the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Ravyn M., Dytfeld, Dominik, Reyes, Leticia, Robinson, Reeder M., Smith, Brittany, Manevich, Yefim, Jakubowiak, Andrzej, Komarnicki, Mieczyslaw, Przybylowicz-Chalecka, Anna, Szczepaniak, Tomasz, Mitra, Amit K., Van Ness, Brian G., Luczak, Magdalena, Dolloff, Nathan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482623/
https://www.ncbi.nlm.nih.gov/pubmed/28415782
http://dx.doi.org/10.18632/oncotarget.16262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482623/
https://www.ncbi.nlm.nih.gov/pubmed/28415782
http://dx.doi.org/10.18632/oncotarget.16262

Ejemplares similares